Diagnostic and prognostic role of peritoneal CA 125 in peritoneal dialysis patients presenting with acute peritonitis
- PMID: 25217152
- PMCID: PMC4169835
- DOI: 10.1186/1471-2369-15-149
Diagnostic and prognostic role of peritoneal CA 125 in peritoneal dialysis patients presenting with acute peritonitis
Abstract
Background: Cancer antigen 125 (CA125) is made by peritoneal mesothelial cells and can be measured in spent dialysate effluent from peritoneal dialysis (PD) patients. It has been suggested that CA125 is a marker of peritoneal mesothelial cell mass and turnover. As PD CA125 increases during peritoneal inflammation, we wished to determine whether measuring PD CA125 during peritonitis provided additional information in determining outcome of peritonitis.
Methods: We prospectively measured peritoneal CA125 in 127 adult PD patients presenting with 187 acute episodes of PD peritonitis, measuring peritoneal CA125 from a sample of dialysate effluent obtained from a 4 hour 2 litre 13.6 g/l dextrose peritoneal dwell.
Results: Mean patient age 60.8 ± 17.1 years, 62.6% male, 33.7% diabetic and the median PD vintage was 22 (11-48) months. 127 patients (66.8%) presented with their first episode of peritonitis, 20% their second episode, 13.2% third or greater. Gram positive bacteria accounted for 64.7% of all peritonitis episodes and Gram negative bacteria 21.1%. Treatment was successful for 151 episodes of PD peritonitis (81.1%). The median PD effluent total WBC was 1240 (430-3660)/ml and serum CRP 67 (20-144) mg/l, with a PD CA125 of 38 (20.3-72.3) IU/l on presentation. There were positive correlations between PD effluent CA125 concentrations and total WBC on presentation (r = 0.41, p = <0.001) and dialysis vintage (r = -0.43, p < 0.001) but not with patient age, diabetic status, or serum CRP.There was no difference in PD effluent CA125 concentrations between Gram positive, and Gram negative peritonitis or between those episodes which responded to treatment, median 38 IU/ml (21-69) vs those with treatment failures 38 IU/ml (15-94).
Conclusion: We did not find any additional diagnostic or prognostic benefit for measuring effluent CA125 in PD patients presenting with acute peritonitis compared to standard investigations, including peritoneal WBC and serum CRP. As such our study would not support the routine measurement of peritoneal CA125 during episodes of peritonitis.
Figures



Similar articles
-
Peritoneal dialysate effluent and serum CA125 concentrations in stable peritoneal dialysis patients.J Nephrol. 2016 Jun;29(3):427-434. doi: 10.1007/s40620-015-0250-9. Epub 2015 Nov 30. J Nephrol. 2016. PMID: 26616639
-
Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis.Perit Dial Int. 2001 Nov-Dec;21(6):560-7. Perit Dial Int. 2001. PMID: 11783764 Review.
-
Expression of cancer antigen 125 by peritoneal mesothelial cells is not influenced by duration of peritoneal dialysis.Perit Dial Int. 2001 Sep-Oct;21(5):495-500. Perit Dial Int. 2001. PMID: 11757834
-
Effects of Icodextrin and Glucose Bicarbonate/Lactate-Buffered Peritoneal Dialysis Fluids on Effluent Cell Population and Biocompatibility Markers IL-6 and CA125 in Incident Peritoneal Dialysis Patients.Ther Apher Dial. 2016 Apr;20(2):149-57. doi: 10.1111/1744-9987.12391. Epub 2016 Mar 1. Ther Apher Dial. 2016. PMID: 26929256
-
Dialysate cancer antigen 125 in long-term peritoneal dialysis patients.Clin Exp Nephrol. 2014 Feb;18(1):10-5. doi: 10.1007/s10157-013-0823-7. Epub 2013 Jun 12. Clin Exp Nephrol. 2014. PMID: 23757048 Review.
Cited by
-
CA-125 and CCL2 may indicate inflammation in peritoneal dialysis patients.J Bras Nefrol. 2021 Oct-Dec;43(4):502-509. doi: 10.1590/2175-8239-JBN-2020-0255. J Bras Nefrol. 2021. PMID: 34032817 Free PMC article.
-
Peritoneal dialysate effluent and serum CA125 concentrations in stable peritoneal dialysis patients.J Nephrol. 2016 Jun;29(3):427-434. doi: 10.1007/s40620-015-0250-9. Epub 2015 Nov 30. J Nephrol. 2016. PMID: 26616639
-
The Versatility of Biological Field-Effect Transistor-Based Biosensors (BioFETs) in Point-of-Care Diagnostics: Applications and Future Directions for Peritoneal Dialysis Monitoring.Biosensors (Basel). 2025 Mar 18;15(3):193. doi: 10.3390/bios15030193. Biosensors (Basel). 2025. PMID: 40136991 Free PMC article. Review.
References
-
- Koomen GCM, Betjes MGH, Zemel D, Krediet RT, Hoek FJ. Dialysate cancer antigen (CA) 125 is a reflection of the peritoneal mesothelial mass in CAPD patients. Perit Dial Int. 1994;14:132–6. - PubMed
-
- Visser CE, Brouwer-Steenbergen JJ, Betjes MG, Koomen GC, Beeleen RH, Krediet RT. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Nephrol Dial Transplant. 1995;10:64–9. - PubMed
-
- Krediet RT. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int. 2001;21:560–7. - PubMed
Pre-publication history
-
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/15/149/prepub
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous